Develops drugs for rare skin disorders like epidermolysis bullosa.
Dec 2023Revenue CHF 6.33M/yrExpenses CHF 117M/yr
No trendCash runway ≈ 10 months from Dec 2023
Figures by year
When will MindMaze Therapeutics Holding be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2023, revenue was CHF 6.33M and expenses CHF 117M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2023 | CHF 6.33M | CHF 117M | −CHF 111M |
| Dec 2022 | CHF 7.11M | CHF 59.1M | −CHF 52.0M |
| Dec 2021 | CHF 4.49M | CHF 38.8M | −CHF 34.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.